Biosergen CEO to BioStock: “Positive data give us a strong value proposition”

Biosergen is carrying out a SEK 40.5 million rights issue to conduct a first-in-patient safety and efficacy study with the antifungal drug candidate BSG005. This will set the stage for the phase II and III clinical studies, which will be financed and undertaken in collaboration with the Indian partner, Alkem. BioStock contacted Biosergen CEO Tine Kold Olesen to get more insights.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/biosergen-ceo-positive-data-give-us-a-strong-value-proposition/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se